Related Experiment Video
Updated: Jan 9, 2026
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer
Lin Lin1, Fushuang Zheng2, Hongyi Wei3
1Department of Respiratory Medicine, Shengjing Hospital of China Medical University, Shenyang 110000, Liaoning, China.
Abstract:
Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited therapeutic options for patients harboring drug-resistant or undruggable targets. PROteolysis TArgeting Chimeras (PROTACs) have emerged as a promising strategy to selectively degrade oncogenic drivers; however, their clinical translation is hampered by systemic toxicity, off-target effects, and poor pharmacokinetics. To address these limitations, conditional and tumor-activated PROTACs have been developed, enabling spatiotemporal control of protein degradation within the tumor microenvironment. Recent advances include light-responsive PROTACs, glutathione- and ROS-activated degraders, enzyme-cleavable linkers, and nanocarrier-based prodrugs that enhance tumor selectivity. In lung cancer, these strategies show particular promise against KRAS, EGFR, and SMARCA2/4-driven malignancies, while also offering synergy with immunotherapy and chemotherapy. This review highlights current design principles, emerging applications, and future perspectives for conditional and tumor-activated PROTACs, underscoring their transformative potential in precision oncology.
Insights
Conditional PROteolysis TArgeting Chimeras (PROTACs) offer targeted lung cancer therapy by degrading oncogenic drivers specifically within tumors. These advanced PROTACs aim to overcome limitations of traditional treatments for improved precision oncology outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Lung cancer is a leading cause of cancer mortality with limited treatment options for resistant or undruggable targets.
- Traditional PROteolysis TArgeting Chimeras (PROTACs) face challenges including toxicity, off-target effects, and poor pharmacokinetics.
- Conditional and tumor-activated PROTACs are being developed to enhance selectivity and control protein degradation within the tumor microenvironment.
Purpose of the Study:
- To review recent advances in conditional and tumor-activated PROTACs for lung cancer treatment.
- To highlight design principles and emerging applications of these targeted therapies.
- To discuss the potential of PROTACs in precision oncology, particularly for KRAS, EGFR, and SMARCA2/4-driven cancers.
Main Methods:
- Review of recent scientific literature on PROTAC technology and its application in lung cancer.
- Analysis of conditional PROTAC designs, including light-responsive, glutathione/ROS-activated, enzyme-cleavable linkers, and nanocarrier-based prodrugs.
- Exploration of synergistic potential with immunotherapy and chemotherapy.
Main Results:
- Conditional PROTACs demonstrate enhanced tumor selectivity and spatiotemporal control of protein degradation.
- Various activation strategies (light, glutathione, ROS, enzymes) and delivery systems (nanocarriers) improve PROTAC performance.
- PROTACs show promise against specific lung cancer drivers (KRAS, EGFR, SMARCA2/4) and can synergize with existing treatments.
Conclusions:
- Conditional and tumor-activated PROTACs represent a significant advancement in precision oncology for lung cancer.
- These strategies hold transformative potential to overcome limitations of current therapies and improve patient outcomes.
- Further research and clinical translation are warranted to fully realize the benefits of advanced PROTAC technology.
